Park Rex, Ho Anthony M-H, Pickering Gisèle, Arendt-Nielsen Lars, Mohiuddin Mohammed, Gilron Ian
School of Medicine, Queen's University, Kingston, ON, Canada.
Department of Anesthesiology and Perioperative Medicine, Queen's University, Kingston, ON, Canada.
JMIR Res Protoc. 2019 Jan 11;8(1):e11654. doi: 10.2196/11654.
Chronic pain is a highly prevalent and complex health problem that is associated with a severe symptom burden, as well as substantial economic and social impact. Many patients with chronic pain still suffer from unrelieved or undertreated pain due to the incomplete efficacy and dose-limiting adverse effects of current therapies. Long-term and high-dose opioid use has considerably increased in the past 20 years despite limited evidence supporting its effectiveness in several chronic pain conditions, and serious concerns have emerged regarding adverse effects and potential misuse. Until recently, the steady increase in opioid prescribing rates has been associated with rising opioid-related mortality and other serious problems, emphasizing the need for better nonopioid therapies. Emerging evidence supports the safe use of magnesium in controlling chronic pain, but its overall efficacy and safety is still unclear.
This paper aims to assess the efficacy and safety of magnesium compared with a placebo for the treatment of chronic noncancer pain.
We will conduct a detailed search on Cochrane Central Register of Controlled Trials, MEDLINE, and EMBASE from their inception until the date the searches are run to identify relevant randomized controlled trials. The reference lists of retrieved studies as well as Web-based trial registries will also be searched. We will include randomized double-blind trials comparing magnesium (at any dose, frequency, or route of administration) with placebo using participant-reported pain assessment. Two reviewers will independently evaluate studies for eligibility, extract data, and assess trial quality and potential bias. Risk of bias will be assessed using criteria outlined in the Cochrane Handbook for Systematic Review of Interventions. Primary outcomes for this review will include any validated measure of pain intensity or pain relief. Dichotomous data will be used to calculate the risk ratio and number needed to treat or harm. The quality of evidence will be assessed using the Grading of Recommendations Assessment, Development and Evaluation approach.
This protocol is grant-funded and has undergone a peer-review process through the Queen's University Department of Anesthesiology and Perioperative Medicine Vandewater Endowed Studentship. This project is also supported, in part, by the Chronic Pain Network of the Canadian Institutes of Health Research Strategy for Patient-Oriented Research. The electronic database search strategies are currently being developed and modified. The entire review is expected to be completed by January 1, 2019.
The completion of this review is expected to identify available high-quality evidence describing the efficacy and safety of magnesium for the treatment of chronic noncancer pain.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/11654.
慢性疼痛是一种高度普遍且复杂的健康问题,与严重的症状负担以及巨大的经济和社会影响相关。由于当前治疗方法的疗效不完全且存在剂量限制的不良反应,许多慢性疼痛患者仍遭受未缓解或治疗不足的疼痛。尽管在几种慢性疼痛病症中支持其有效性的证据有限,但在过去20年中,长期和高剂量使用阿片类药物的情况大幅增加,并且对其不良反应和潜在滥用问题已引起严重关注。直到最近,阿片类药物处方率的稳步上升与阿片类药物相关死亡率及其他严重问题的增加有关,这突出了对更好的非阿片类治疗方法的需求。新出现的证据支持安全使用镁来控制慢性疼痛,但其总体疗效和安全性仍不明确。
本文旨在评估镁与安慰剂相比治疗慢性非癌性疼痛的疗效和安全性。
我们将对Cochrane对照试验中央注册库、MEDLINE和EMBASE进行详细检索,从其创建至检索日期,以识别相关的随机对照试验。还将检索检索到的研究的参考文献列表以及基于网络的试验注册库。我们将纳入使用参与者报告的疼痛评估方法,比较镁(任何剂量、频率或给药途径)与安慰剂的随机双盲试验。两名评价者将独立评估研究的合格性、提取数据并评估试验质量和潜在偏倚。将使用《Cochrane干预措施系统评价手册》中概述的标准评估偏倚风险。本综述的主要结局将包括任何经过验证的疼痛强度或疼痛缓解测量指标。将使用二分数据计算风险比以及治疗或伤害所需的人数。将使用推荐分级评估、制定和评价方法评估证据质量。
本方案由基金资助,并已通过女王大学麻醉学与围手术期医学系范德沃特捐赠奖学金进行了同行评审。该项目还部分得到了加拿大卫生研究院以患者为导向的研究战略慢性疼痛网络的支持。目前正在制定和修改电子数据库检索策略。整个综述预计于2019年1月1日前完成。
预计本综述的完成将识别出描述镁治疗慢性非癌性疼痛的疗效和安全性的现有高质量证据。
国际注册报告识别码(IRRID):PRR1-10.2196/11654